Ben Daverman


Ben joined GTCR in 2008 and became a Principal in 2014. Prior to joining GTCR, he worked as a Venture Capitalist at Alta Partners, as well as an Investment Banking Associate at JMP Securities and an Analyst in the Mergers & Acquisitions group at J.P. Morgan (formerly Hambrecht & Quist). He is currently a Director of Cole-Parmer, Maravai LifeSciences, TerSera and XIFIN. Ben was previously a Director of past GTCR investments such as Actient Pharmaceuticals, Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix and Sterigenics. In addition, Ben was involved in GTCR’s investment in Graceway Pharmaceuticals. Ben is active in the community and serves on the executive board of Spark Program, a national non-profit that provides transformative apprenticeships for at-risk middle-school students.